Conference Coverage: ASCO 2022 – Focus on Lung Cancer

Expert perspectives and strategic insights on the latest therapeutic developments and translational research in lung cancer treatment

June 13, 2022
Corey Langer MD Scientific Leader Faculty Chair Aptitude Health

Faculty Chair

Corey J. Langer, MD, FACP

University of Pennsylvania, Philadelphia, PA, USA


Solange Peters, MD, PhD
University of Lausanne, Switzerland

Roy Herbst, MD, PhD
Yale Cancer Center, New Haven, CT,  USA

Enriqueta Felip, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain

David Spigel, MD
Sarah Cannon Cancer Institute, Nashville, TN, USA

Mark Socinski, MD
AdventHealth Cancer Institute, Orlando, FL, USA

Paul Paik, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Lynette Sholl, MD
Dana-Farber Cancer Institute, Boston, MA, USA

Sample Report

Start discovering the insights

View Report


  • Immunotherapy in Stage I–III NSCLC
  • Immunotherapy in Stage IV NSCLC
  • EGFR (common mutations): Resectable and Metastatic
  • EGFR (exon 20 and other uncommon mutations)
  • Oncogenic Fusions
  • Oncogenic Mutations
  • Other Targets in NSCLC/SCLC

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.